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Abstract- Screening mammography among women with a family history of breast cancer
Lauren Hibler, Anees Chagpar
Women with a first degree family history of breast cancer are at increased risk of developing this disease.
Screening with mammography has been demonstrated to detect cancer early, when it is most treatable.
We hypothesized that, due to their increased risk, women with a first degree family history of breast
cancer would be more likely to obtain screening mammograms than the general population. We further
sought to determine the self-reported reasons for failing to adhere to screening guidelines in this high risk
population.
The National Health Interview Survey (NHIS), conducted annually by the Centers for Disease Control, is
designed to be representative of the US population. The 2010 NHIS Cancer Supplement was used to
evaluate the rates of mammography, predictors of screening, and the most common reasons cited for not
having a mammogram, in the previous two years in women with and without a first degree family history
of breast cancer.
Overall, 78.5% of women reported obtaining a screening mammogram in the previous two years. Women
with a first degree family history had similar rates of screening mammography as average risk women.
(79.5% vs 78.4% p=0.452). On multivariate analyses, income to poverty line ratio, and access to
preventive health care services were independently associated with screening mammography in both
average and high risk cohorts. The reasons women overall cited for not obtaining a screening
mammogram (irrespective of risk cohort) were: “Never thought about it,” “Doctor didn’t say I needed it,”
and “Too expensive, or Didn’t have insurance.”
These data demonstrate that high risk populations are not more likely to adhere to screening guidelines
for breast cancer than their average risk counterparts, and that the main factors influencing adherence
were income, insurance, and access to preventive health services. These findings suggest that social
determinants of health affect screening, and addressing key issues such as access and cost of healthcare is
critical to improving rates of screening mammography, especially in high risk groups.
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1
A brief history of breast cancer

Breast cancer is a disease that has been known since ancient times. The oldest
documented description of breast cancer is from 1600 BC Egypt. The Edwin Smith papyrus
describes 8 cases of breast tumors, from palpable lumps to ulcerating masses, and concludes for
all of them, “There is no treatment.” [1]

No advances were made in treatment until the 1700s, when surgery to remove the
breast and surrounding tissues, as well as the lymph nodes under the armpit, was explored.
William Stewart Halsted, aided by advances in anesthesia and aseptic technique, successfully
developed the radical mastectomy, and reduced local recurrence rates from 51% to 6%% [2, 3].
Though successful, it was also disfiguring and led to long term discomfort and disability.

The surgical approach remained the only treatment option until the early 1900s, when
radiation therapy became available, although it was not widely used until the 1930s [4]. Further
advances in cancer understanding and treatment options have improved the care of breast
cancer.

While care has improved, incidence rates of breast cancer have remained fairly stable.
In 1988, the incidence of breast cancer was 220 cases per 100,000 woman years. Incidence
steadily rose to a peak of 232 cases per 100,000 woman years in 1999 [5]. There was a sharp 7%
decrease in incidence from 2002-2003, following the cessation of long term hormone
replacement therapy [6, 7]. Since 2003, incidence of breast cancer has been approximately 200
cases per 100,000 woman years, and is projected to remain stable, or slightly increase through
2016 [5, 8]. Overall, a woman’s lifetime risk of developing breast cancer is 1/8 [9].
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Besides skin cancer, breast cancer is the most common malignancy in US women, with
232,340 cases diagnosed in 2013. It is the second leading cause of cancer death, with 39,620
deaths in 2013 [9].

Risk factors for breast cancer

While 12% of women in the general population will experience breast cancer in their
lives, there are risk factors that increase the chance of developing the disease. The two greatest
risk factors for breast cancer are female sex and increasing age. Approximately 1% of all breast
cancers are diagnosed in men. While men may possess some breast tissue, in most it is not
developed as it is in women, and not sensitive to hormone changes [10]. As all people age, their
risk of any type of cancer increases. Specifically for breast cancer, approximately 67% of invasive
breast cancers are found in women 55 and older [11].

Family history is the next strongest risk factor for breast cancer. In general, women with
a first degree family history (meaning a mother, father, sister, or brother affected by the
disease) have twice the risk of developing breast cancer as the general population [12-15].

The risk increases as more family members are diagnosed, and as they are diagnosed at
a younger ages. For women whose mother was diagnosed at or before age 30, the relative risk is
4.3 and if a sister was diagnosed at or before 30, the relative risk is 9.4, compared to women
without a family history. Having multiple family members affected further increases the risk,
from a relative risk of 5.9 when a mother and sister are diagnosed by the age of 50, to a relative
risk of 17.1 for a mother and 2 sisters diagnosed by the age of 50 compared to no family history
of breast cancer [16]. Those women with a first degree family history of breast cancer make up
12.5% of the population, and account for 15-20% of all cases of breast cancer [17]. Other risk
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factors include hormone replacement therapy, obesity, early menarche, late menopause, and
nulliparity, all of which have to do with increased exposure to estrogen [12].

Mammography use reduces breast cancer mortality

Great strides have been made in breast cancer beyond Halsted’s radical mastectomy.
Radiation therapy, adjuvant and anti-estrogen therapies, and screening mammography are all
advances that have contributed to decreased mortality due to breast cancer.

The effectiveness of radiotherapy and adjuvant therapy is well documented and rarely
disputed [18-20]. However, in the past decade and a half, the benefits and risks of routine
screening mammography have been debated.

The goal of screening mammography is to find breast lesions earlier in their natural
history than they would be found on clinical or self-breast exam. By finding lesions earlier, they
are less likely to have metastasized and so can be treated with less toxic therapy and survival
can be increased [21].

Since the introduction of mammography as a tool, 8 randomized control trials [22], and
more observational studies, have been done on the effectiveness of mammography at reducing
breast cancer mortality. Four of the randomized control trials took place in Sweden [23-26], one
in Scotland [27], one in New York [28] and two in Canada [29, 30]. All but one of the Canada
studies compared screening with no screening. The exception compared screening with an
initial, one time clinical breast exam for both the control group [29]. They differed, however, in
the years the study was conducted and followed up, recommended screening intervals and
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number of visits, type of screening mammography, method of group assignment, and method of
analysis [22].

On the basis of these studies, most of which showed a significant reduction in breast
cancer mortality from screening, as well as the observation that in areas where screening
mammography was in use breast cancer mortality rates were dropping, screening
mammography was believed to be lifesaving [31].

In the United States by the end of the 1990s, 71% of women 40 years and older had a
screening mammogram in the previous two years, and breast cancer mortality had dropped to
27 deaths per 100,000 women, its lowest rate since 1973 [22]. A meta-analysis including eight
randomized control trials and four case-control studies found a relative risk of breast cancer
mortality of 0.74 (95% CI 0.66-0.83) for screened versus unscreened women ages 50 to 74 [32].
Another meta-analysis found in seven randomized control trials including women aged 40 to 49,
there was a relative risk of breast cancer mortality of 0.85 (95% CI 0.73- 0.99) for screened
versus unscreened women in the 40 to 49 year age cohort [33]. With this evidence, many major
cancer fighting groups recommended routine screening mammography for women 50 to 69
years of age, and some for screening mammography for women 40 to 49 years of age [22].

Then, in 2000, a widely cited meta-analysis by Gotzsche and Olson claimed that, of the 8
randomized control trials, six were so flawed that they could not be reliably included in any
analysis [34]. Their meta-analysis of the 2 adequately randomized trials found no reduction in
breast cancer mortality (Relative Risk 1.04 CI 0.84-1.27). They further argued that breast cancer
mortality was not a reliable outcome measure, as they believe cause of death for women in the
screening arm was biased towards a cause other than breast cancer [35]. They calculated
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relative risk of all-cause mortality for screening versus unscreened groups and found 0.99 (95%
CI 0.94-1.05)

In addition to the harms that may increase mortality, they noted screening was
associated with an increase in the number of mastectomies by 20% and lumpectomies by 30% in
the screened versus unscreened groups .

After discussing these findings, and the merits and failures of the analysis, the 2002 National
Health Council of the Netherlands reported “The committee sees no scientific basis in light of
the Cochrane Review to conclude that population screening for breast cancer for women over
the age of 50 has no survival benefit.” The cited disagreements with trial exclusion, and the
replacement of breast cancer mortality with all-cause mortality. Their meta-analysis produced a
relative risk of breast cancer mortality for the invited to screening versus unscreened of 0.72
(95% CI 0.61-0.85)[36].

The independent UK Panel on Breast Screening utilized 11 randomized control trials for
their analysis and found a breast cancer mortality relative risk of 0.80 (95% CI 0.73-0.89) for
those invited to screening versus those not screened. They also estimated that for every 235
women invited to screening, 1 life would be saved. Though they acknowledged uncertainties in
the trials included, they still concluded that “Breast Cancer screening extends lives.” [37]

The United States Preventive Services Task Force released their own set of
recommendations using the same trials as Gotzsche and Olsen, but agreed that while the trials
were only “fair” quality, this was not grounds for exclusion from the meta-analysis. The group
reported a relative risk of breast cancer mortality of 0.84 (0.77-0.91) for the invited to screening
women versus the unscreened women. They recommended screening mammography every 1 to
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2 years for all women aged 40 and older [38]. In 2009, they updated their recommendations,
still only taking into account randomized control trials. Their recommendation was for women
50 to 69 to have regular screening mammograms, based on evidence that indicated a 15%
mortality reduction [39].

The arguments came down to how to judge randomized control trials. Steven Goodman
of Johns Hopkins Cancer Center said of the debate:

“One of the main tenants of evidence based medicine is that scientific demonstrations of
efficacy, from randomized, controlled trials or carefully designed population studies, should
supersede expert opinions about efficacy. However, this controversy shows that the justification
for why studies are included or excluded from the evidence base can rest on competing claims
of methodological authority that look little different from the traditional claims of medical
authority that proponent of evidence based medicine have criticized.” [40]

All of the recommendations insisted on discussing the benefits and risks of screening
mammography with their patients, which in light of the debate about which trials are
scientifically accurate seems even more prudent [36-38].

If we consider all studies of screening mammography’s effect on breast cancer
mortality, we can include observational and case control studies. An observational study with
data from 20 years before and after the introduction of screening mammography, after
adjustment for age, self-selection bias, and changes in breast cancer incidence, found the
relative risk of breast cancer mortality was 0.56 (95% CI 0.49-0.64) for women exposed to
screening versus women before screening was introduced in the 40 to 69 year old age group.
Comparing women not exposed to screening despite its introduction to women before the
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introduction of screening gave a relative risk of 0.84, indicating some, but not all, of the
mortality reduction is due to factors other than screening mammography [41].

A study using the British Columbia screening mammography program calculated a
relative risk of breast cancer mortality of 0.76 for screened versus unscreened women older
than age 40 after correcting for self-selection bias as well as income [42].

Because of the argument about randomized control trials, and the value of
observational and case control studies, the Wolfson Institue of Preventive medicine summarized
the non-randomized evidence from 1990 onward. They found a relative risk of breast cancer
mortality of 0.74 (95% CI 0.67-0.82) associated with invitation to screening. When they
considered only those women who were actually screened and adjusted for self-selection bias,
the relative risk of breast cancer mortality found was 0.68 (0.61-0.76) [43].

Evidence for the women 39-49 is less clear than the evidence for women 50-69,
however, some researchers attempted to pool data to find a stronger conclusion. A metaanalysis in 2009 used the 8 randomized control trials and found a relative risk of breast cancer
mortality of 0.85 (95% CI 0.75-0.96) for invitation to screening versus control, of the 39 to 49
year age group [44].

Another analysis utilizing data only from the Netherlands trials found a relative risk of
breast cancer mortality of 0.50 (95% CI 0.30-0.82) for screened versus unscreened women 40 to
49 years of age, however, they did not take into self-selection bias [45].

So it would seem that breast cancer mortality is indeed decreased by screening
mammography. Some have argued that reduction in mortality is in fact due to better treatment
options. In 2005 a consortium of investigator developed 7 independent models of breast cancer
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incidence and mortality. Their data set came from the following databases for the years 1975 to
2000:

The National Health Interview Survey

The Surveillance Epidemiology and End Results Patterns of Care

The Breast Cancer Surveillance Consortium

The Surveillance Epidemiology and End Results 9

The Connecticut Tumor Registry

The Human Mortality Database

The National Center for Health Statistics

They determined that the total reduction in deaths due to breast cancer that can be credited to
screening ranged from 28 to 65% with a median of 46%. They determined adjuvant treatment
contributed the rest [46]. Thus, while some reduction in breast cancer mortality is due to
advances in treatment, screening mammography plays an important role as well.

Mammography use allows for less toxic therapy

In addition to reducing mortality, screening mammography allows patients to be treated
with less toxic therapy. One study using data from the Dartmouth Medical Center found that for
breast cancers found on screening mammography compared to those found on physical exam,
they were significantly smaller on average (1.5 cm versus 2.9 cm, p<0.0001) and significantly less
likely to be node positive (16% versus 42%, p<0.0001) [47].
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Being smaller and less advanced, the screening detected breast cancers were more
likely than physical exam detected breast cancers to be treated with breast conservation (56%
versus 32%, p<0.0001) and less likely to receive systemic chemotherapy (28% versus 56%,
p<0.0001). On a multivariate analysis controlling for age, women whose tumor was found on
physical exam were 2.9 times (95% CI 2.1-3.9) as likely to have chemotherapy and 2.5 times
(95% CI 1.9-3.3) as likely to have a mastectomy than women whose cancer was found on
screening mammography [47].

A 2007 study from the Swedish Organized Service Screening Evaluation Group found
that with the introduction of screening mammography, there was a significant 45% reduction in
tumors larger than 2 cm in the 40-49 year age group, and a significant 33% reduction in the 5069 year age group. Both groups also had lower rates of node positive cancers after screening
was introduced (40 to 49 age group- 29% reduction; 50 to 69 age group- 16% reduction) [48].

Risks associated with mammography use

While it seems that on the whole, mammography reduces breast cancer mortality, it is
not without its risks. Investigators have raised concerns about overdiagnosis, false positive
mammograms, and undue anxiety brought on women.

A recent study compared the rates of early and advanced disease from pre- screening
mammography introduction to recent years when screening mammography was used by 70% of
women. They found that while there was an absolute increase of 122 cases of ductal carcinoma
in situ and localized disease per 100,000 women years, there was only a reduction of 8 cases of
advanced disease for 100,000 women years [49].
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A different study from Europe found the rate of overdiagnosis to be only 7%. The
purpose of their study was to evaluate the trials from Europe for appropriate methodology, and
determine if the mortality reductions were really due to screening mammography. Through
meta-analysis, they determined their much lower overdiagnosis rate [50].

The large difference in these overdiagnosis rates has most to do with the method of
modeling the trend of incidence. No particular method of modeling is scientifically favored over
another, so there is no reason to trust one of these studies over the other [21].

Another way to determine the overdiagnosis rate is to compare incidence rates of
screening women versus control groups not offered screening after the trial. Using this method,
the Independent UK Panel on Breast Cancer Screening found a rate of overdiagnosis of 19%
(19% of cancers diagnosed during screening would not have been clinically apparent in the
woman’s lifetime); that is, for every 10,000 women invited to screening mammography, a total
of 681 cancers (both invasive and ductal carcinoma in situ) would be diagnosed, of which, 129
would be overdiagnoses. 43 deaths from breast cancer would be prevented [37].

In addition to overdiagnosed cases, there are false positive mammograms. Nationally,
11% of screening mammograms require further evaluation. 3% of those 11% are found to be
cancer (0.3% of all mammograms) [22]. After 10 mammograms, each, up to 49% of women will
experience a false positive result, and 19% will have a biopsy [51].

The women receiving call backs have higher levels of anxiety, although generally it is not
to a clinically diagnosable level, and the anxiety is not sustained [52]. Schwartz in 2000 surveyed
women regarding their knowledge and tolerance of false positives. She found that 99% of
women knew that false positives were a risk of screening mammography. Further, she found
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that 63% of women thought that 500 or more false positives was a reasonable trade-off for 1 life
saved [53]. The meta-analysis from 1993 with the eight randomized control trials and four case
control trials estimated that for each life saved, there were between 3 and 200 false positive
mammograms [32], thus the majority of women surveyed would tolerate well above the actual
number of false positives.

Regarding overtreatment of ductal carcinoma in situ cases, Schwartz also asked women
“at what threshold for the chance of ductal carcinoma in situ becoming invasive, would [they]
want treatment?” 42% of women wanted to be treated with even a 1% chance of progression.
Another , 38% of women said they would want to be treated if there was a 33% risk of
progression [53]. Estimates for progression of ductal carcinoma in situ to invasive cancer put it
up to 33% [54].

Recommendations from major health organizations

Taking into account all the evidence, major health organizations have released their
recommendations for mammography screening guidelines. Most recommended routine
screening mammography for women 50-69 either annually or every two years. For women 4049, most still recommended screening, but made it clear that the risks and benefits should be
thoroughly discussed as the mortality benefit may not be as great in this age range as in the
older cohort. [39, 55-62] (Table 1)
Table 1- Screening guidelines from major health
organizations

Group

Age

Frequency

40-49

50-69

>69
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American Academy of Family Physicians 2012 [55]

2

No

Yes

No

American Cancer Society 2013 [56]

1

Yes

Yes

Yes

American College of Obstetrics and Gynecologists

1-2 if 40-49, 1 if

Yes

Yes

Yes

2011 [57]

>49

American College of Radiology 2012 [58]

1

Yes

Yes

Yes

American Medical Association 2012 [59]

1

Yes

Yes

Yes

Canadian Task Force on Preventive Health Care

2-3

No

Yes

Yes

National Cancer Institute 2012 [61]

1-2

Yes

Yes

Yes

National Comprehensive Cancer Network [62]

1

Yes

Yes

Yes

US Preventive Services Task Force 2009 [39]

2

No

Yes

Yes

2011 [60]

Mammography in the family history population

The efficacy of screening mammography on reducing breast cancer mortality mostly
focused on the women at average risk of developing breast cancer. Few studies however have
looked at screening in the higher risk first degree family history cohort. To our knowledge, there
are no randomized trials comparing screening mammography to no screening and reduction of
breast cancer mortality solely within the first degree family history population. Some
investigators have studied, however, the rates of breast cancer detection in women with a first
degree family history compared to those without it.

Kollias in 1997 studied the cancer detection rates in women younger than 50, who had
increased risk of developing breast cancer based on family history. The group was followed for 8
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years, and 29 cases were detected in 1371 women by a combination of screening
mammography and clinical breast exam. Compared to age matched females, the first degree
family history group had a relative risk of invasive breast cancer of 5.0. Compared to women 50
years and older, not at higher risk, cancer screening detection rates were similar, i.e. women at
increased risk had rates of breast cancer similar to women a decade older [63].

Kerlikowske also studied cancer detection rates in women with a first degree family
history of breast cancer and compared them to the general population. He too saw that higher
risk women have a greater number of cancer cases per 1000 exams than the average risk group.
For the women aged 40 to 49, the numbers were 4.7 versus 2.7 for higher risk versus general
population. He also found that women with a first degree family history had similar rates of
cancer as the average risk women a decade older (Higher risk 40-49 years olds- 4.7, Average risk
50-59 year olds- 4.6) [64].

So women with a first degree family history not only are at increased risk of developing
breast cancer over their life time, but screening programs are effective ways of catching these
cases of breast cancer before they progress to advanced disease.

We can extrapolate that if screening mammography confers a breast cancer mortality
reduction to average risk women, and screening mammography is effective at discovering
breast cancers in women with a first degree family history, then screening mammography would
also reduce breast cancer mortality in this higher risk population, possibly to a greater
magnitude than the average risk group given the greater risk of early disease.
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Aims and Hypotheses

Our aims were to:

A) Determine whether women with a first degree family history of breast cancer are more likely
to obtain a screening mammogram than women without a first degree family history,
independent of other factors

B) Determine what reasons the women who did not obtain screening mammograms cite for
their non-adherence

We hypothesized that, because of their increased risk, and the emotional and
psychological burden of being at increased risk, women with a first degree family history of
breast cancer would be more likely to undergo screening mammography than women without
the first degree family history.

For the women with a family history who did not obtain a screening mammogram, we
hypothesized they would have varied reasons, however, “Never thought about it,” would not be
one of the most cited reasons. Surely, the anxiety from seeing a family member suffer with
breast cancer would be motivation to think about getting a mammogram, and so there must be
another reason for failing to be screened.
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Trends in mammography

From 1987 to 2000, screening mammography rates rose from 39.1% to 70.1% [65].
However, despite success in reducing breast cancer mortality, rates of screening mammography
began to drop. Prompted by lay literature that Medicare claims for screening mammography
were declining, a non-profit group model Health Maintenance Organization in the Pacific
Northwest investigated the screening mammography rates for the women in their group. They
found from 1999 to 2002, the percentage of eligible screening time appropriately covered by a
screening mammogram fell from 67% to 62.5% [66].

On a national level, using data from the 2000 and 2005 National Health Interview Survey
database, it was determined that rates of women who obtain screening mammograms within
the past two years significantly decreased from 70% in 2000 to 66% in 2005 [67]

Chagpar in 2007 using the National Health Interview Survey database found that of the
women not having had a mammogram in the past two years, most cited “Never thought about
it” as their reason for not obtaining a mammogram. Analyzing sociodemographic factors,
Chagpar found that income, education, and markers of access predicted mammography usages,
but race did not [68].

Slomiany then investigated whether women with a first degree family history also had a
decline in screening mammography rates. Compared to the general population who had a
decline of 67.0% to 63.9% (p=0.0006), these higher risk women had a smaller decline, from
82.7% in 2000 to 79.8% in 2005, that did not reach statistical significance (p=0.1328). The higher
risk women remained more likely to have a screening mammogram in the previous two years
than the average risk women (79.8% versus 63.9% p<0.0001) [69].
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Methods

Data from the 2010 National Health Interview Survey (NHIS) database and cancer
supplement were gathered. This is a face-to-face population-based health survey designed to be
representative of the American civilian non-institutionalized population. The survey has been
conducted annually since 1957 by the National Center for Health Statistics, Centers for Disease
Control and Prevention, and consists of two components: a “Basic Module” containing basic
health and demographic information, and “Supplements” which relate to specific areas of
interest. Every five years, including 2010, the “Supplement” concerns cancer screening and
incidence. The Basic Module, which remains largely unchanged from year to year, consists of 3
components: the Family Core, the Sample Child Core, and the Sample Adult Core. Information
collected for all family members includes household composition and socio-demographic
characteristics among other factors. From each family in the NHIS, one sample child (if any
children under age 18 are present) and one sample adult are randomly selected, and
information on each is collected with the Sample Child Core and the Sample Adult Core
questionnaires. In 2010, sample adults also completed the cancer supplement, which collected
information regarding use of mammography and other cancer screening modalities.

Nationally, the NHIS uses about 400 interviewers, trained and directed by health survey
supervisors in the 12 U.S. Census Bureau Regional Offices. The interviewers receive training on
an annual basis in basic interviewing procedures and in the concepts and procedures unique to
the NHIS. The NHIS is conducted using computer-assisted personal interviewing (CAPI). This
method presents the questionnaire on computer screens to each interviewer and guides the
interviewer through it, automatically routing the interviewer to appropriate questions based on
answers to previous questions. Interviewers enter survey responses directly into the computer,
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and the CAPI program determines if the selected response is within an allowable range, checks it
for consistency against other data collected during the interview, and saves the responses into a
survey data file. This technology reduces the time required for transferring, processing, and
releasing data, and ensures the accurate flow of the questionnaire. The survey sample is reevaluated every 10 years in order to better reflect the changing U.S. population. The sample is
chosen in such a way that each person in the U.S. population has a known non-zero probability
of selection. The probability of selection, along with 9 adjustments for nonresponse and poststratification, are reflected in the sample weights that are provided in the data files provided by
the NHIS. These weights, which account for the multistage sample design to reflect the civilian
non-institutionalized population of the United States, are used for data analysis. In addition to
the design and ratio adjustments, weights are further modified by adjusting them to the 2010
Census-based population estimates for sex, age, and race/ethnicity populations (poststratification). Because of this complex sample design involving stratification, clustering, and
multistage sampling, and the resulting adjusted sampling weights, statistical software that
provides the capability of variance estimation and hypothesis testing for complex sample
designs (e.g. Survey Data Analysis (SUDAAN)) is needed.

In 2010, the NHIS survey included 27157 adults with an average response rate of 60.8%.

After determining the rate of a first degree family history and mammography, for the whole
population of women aged ≥ 40, we divided the women into two groups: those with a first
degree family history of breast cancer and those without. We analyzed rates of mammography
in the past year for both groups. We also analyzed other possible confounding factors and
performed a multivariate analysis controlling for age, race, personal history of breast cancer,
income, insurance, education, region, and access to a health care professional. A second
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multivariate analysis was performed on the first degree family history cohort and testing for
these possibly significant predictors.

To determine reasons women cite for non-adherence, we analyzed the group of women
who did not have a mammogram within the past two years for their answer to the supplement
question, “What is the most important reason why you have a) NEVER had a mammogram or b)
NOT had a mammogram in the PAST 2 YEARS?” Possible responses were: “Never thought about
it,” “Didn’t need it,” “Doctor didn’t say I needed it,” “Haven’t had any problems,” “Put it off,”
“Too expensive, or no insurance,” “Too painful, unpleasant, or embarrassing,” “Too young,”
“Don’t have a doctor,” and “Other.”

We performed the analysis on the population of all women over 40 who had not had a
mammogram in the past two years. For each possible response we assessed whether women
with a first degree family history were more likely to cite that reason than women without a
family history.

All statistics were performed using SAS Version 9.0.1 (SAS, Cary, NC, USA) and Survey
Data Analysis (SUDAAN) software (Research Triangle Institute, Research Triangle Park, NC, USA.

Statement of Work

In consultation with my thesis advisor, I discussed my interest in preventing advanced
disease as a focus for this thesis. I was directed to the Nation Health Interview Survey as a
possible data source. After determining my specific question and conducting a literature search,
I developed my hypothesis and determined the fields needed to test it. I coded these fields as
would be need for analysis in SUDAAN. While my advisor has the expertise in programming
SUDAAN, I participated in the process and learned the general framework of this program. I

19
familiarized myself with the statistical analyses employed, and was responsible for analyzing the
resulting output. Subsequent to the initial analysis, I proposed post-hoc analyses when
necessary. I wrote two abstracts resulting from this work, presented at 2 national meetings, and
intend to submit 2 papers to peer reviewed journals. In addition, this thesis is entirely my own
work.
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Results

In 2010, the National Health Interview Survey included 9631 women over the age of 39
representing the 73,448,042 women over the age of 39 in the United States population. Overall
78.5% of women reported having had a screening mammogram in the previous two years.

Of the women surveyed, 12.5% had a first degree family history of breast cancer.
Presence of family history varied with age, personal history of breast cancer, race,

education, insurance, and poverty ratio, but not region. (Table 2)
Table 2Univariate comparison of sociodemographic factors by first degree family history status (FDFHx)
Percentage (%) of women over 39 years of age

Age

Personal History

Race

Overall

(+) FDFHx

(-) FDFHx

p-value

40-49

29.59

19.49

31.04

<0.01

50-59

28.21

27.97

28.24

60-69

21.06

26.65

20.26

70-79

12.3

17.18

11.61

80+

8.83

8.70

8.85

Yes

4.21

7.91

3.68

No

95.79

92.09

96.32

Hispanic

10.06

6.02

10.64

White

73.17

81.50

71.97

Black

11.37

8.89

11.73

Asian

4.47

2.36

4.78

<0.01

<0.01
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Education

Other

0.93

1.23

0.89

Some High

14.46

11.81

14.84

High School

29.1

29.63

29.03

Some College

29.41

28.58

28.58

Bachelors

16.91

19.26

19.26

Masters

8.00

7.77

7.77

Prof/ Doc

2.12

2.12

2.00

Not Covered

11.12

6.27

11.83

Medicare

33.23

40.23

32.20

Medicaid

3.93

2.80

4.09

Military

1.66

2.04

1.61

Private

50.06

48.57

50.28

<1

12.31

8.61

12.85

1-1.99

17.71

15.47

18.04

>2

69.97

75.92

69.12

Northeast

19.01

19.48

18.94

Midwest

22.97

23.24

22.94

South

35.36

36.47

35.20

West

22.66

20.81

22.92

<0.01

School

Insurance

Income to poverty line ratio

Region

<0.01

<0.01

0.6381
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On univariate analysis, women with a first degree family history had similar rates of
screening mammography as those women without the family history. (79.5% versus 78.4%
p=0.4521). (Table 3)
Table 3Univariate comparison of sociodemographic factors by screening mammography (MMG) status
Percentage (%) of women over 39 years of age
(+) MMG

(-) MMG

78.54

21.46

Yes

79.50

20.50

No

78.40

21.60

40-49

81.84

18.16

50-59

80.17

19.83

60-69

80.40

19.60

70-79

75.95

24.05

80+

61.98

38.52

Yes

82.47

17.53

No

78.37

21.63

Hispanic

80.79

19.21

White

77.83

22.17

Black

79.89

20.11

Asian

81.98

18.02

Other

77.61

22.39

Some High School

73.00

27.00

Overall
First Degree Family History

Age

Personal history of breast cancer

Race

Education

p-value

0.452

<0.01

0.0793

0.0687

<0.01
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Insurance

Income to poverty line ratio

Region

High School

76.67

23.33

Some College

78.05

21.93

Bachelors

82.93

17.07

Masters

84.94

15.06

Prof/ Doc

89.11

10.89

Not Covered

67.98

32.02

Medicare

72.31

27.69

Medicaid

82.09

17.91

Military

90.28

9.72

Private

84.36

15.64

<1

72.96

27.04

1-1.99

70.14

29.86

>2

81.83

18.17

Northeast

82.75

17.25

Midwest

78.61

21.39

South

77.28

22.72

West

76.91

23.09

<0.01

<0.01

0.0004

On a multivariate analysis of all US women over 39 years of age, controlling for first
degree family history, insurance status, age, education, race/ ethnicity, region, income to
poverty line ration, personal history of breast cancer, and access to preventative care, women
with a first degree family history were still no more likely to obtain a screening mammogram in
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the previous two years than their average risk counter parts (OR- 1.04 95% CI 0.86-1.26). (Table
4)
Table 4Odds Ratios, Factors affecting screening mammography (MMG) in US women aged 40 and older

First degree family history

Age

Personal history of breast cancer

Race

Education

Odds Ratio (95% CI)

p-value

Yes

1.02 (0.85-1.24)

0.7047

No

1.00

.

40-49

1.08 (0.81-1.45)

0.5186

50-59

0.98 (0.74-1.30)

0.9427

60-69

1.12 (0.87-1.44)

0.3771

70-79

1.00

.

80+

0.63 90.5-0.8)

0.0001

Yes

1.27 (0.89-1.81)

0.1931

No

1.00

.

Hispanic

1.67 (1.32-2.10)

<0.0001

White

1.00

.

Black

1.33 (1.11-1.60)

0.0044

Asian

1.4 (1.02-1.92)

0.0345

Other

0.93 (0.47-1.82)

0.8633

Some High School

1.00

.

High School

1.07 (0.88-1.29)

0.5275

Some College

1.06 (0.86-1.31)

0.5404

Bachelors

1.34 (1.04-1.73)

0.0258
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Insurance

Income to poverty line ratio

Region

Access to preventive care

Masters

1.35 (0.94-1.95)

0.1046

Prof/ Doc

1.94 (1.08-3.49)

0.0275

Not Covered

1.00

.

Medicare

1.50 (1.15-1.95)

0.0715

Medicaid

2.30 (1.59-3.33)

0.0005

Military

3.69 (1.66-2.62)

0.0002

Private

2.09 (1.66-2.62)

0

<1

1.00

.

1-1.99

0.93 (0.75-1.14)

0.5868

>2

1.40 (1.14-1.71)

0.0016

Northeast

1.47 (1.21-1.79)

0.0003

Midwest

1.16 (0.96-1.39)

0.1531

South

1.00

.

West

0.94 (0.77-1.14)

0.5476

Yes

1.66 (1.23-2.23)

0.0009

No

1.00

.

Having insurance, higher income, and access to preventive care were significantly
associated with rates of screening mammography.

On a stratified multivariate analysis of just the US women over 39 with a first degree
family history of breast cancer having insurance, higher income, and access to preventive care
were significantly associated with rates of screening mammography. (Table 5)
Table 5-
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Odds Ratios, Factors affecting screening mammography (MMG) in women with a first degree family
history of breast cancer aged 40 and over
Variable
Age

Personal history of breast cancer

Race

Education

Insurance

Odds Ratio (95% CI)

p-value

40-49

0.95 (.38-2.36)

0.9105

50-59

1.11 (0.50-2.45)

0.8007

60-69

1.47 (0.73-2.95)

0.2819

70-79

1.00

.

80+

0.78 (0.39-1.56)

0.4837

Yes

0.88 (0.44-1.77)

0.7168

No

1.00

.

Hispanic

3.01 (1.41-6.41)

0.0044

White

1.00

.

Black

2.18 (1.14-4.17)

0.0183

Asian

0.67 (0.17-2.62)

0.5666

Other

0.62 (0.17-2.26)

0.4714

Some High School

1.00

.

High School

0.56 (0.28-1.12)

0.1023

Some College

0.62 (0.30-1.27)

0.1879

Bachelors

0.70 (0.33-1.48)

0.3514

Masters

0.66 (0.24-1.81)

0.4182

Prof/ Doc

1.09 (0.34-3.47)

0.8898

Not Covered

1.00

.

Medicare

2.21 (0.95-5.11)

0.0639
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Income to poverty line ratio

Region

Access to preventive care

Medicaid

3.07 (1.00-9.41)

0.0498

Military

.

.

Private

3.61 (1.71-7.64)

0.0008

<1

1.00

.

1-1.99

1.46 (0.58-2.33)

0.679

>2

2.39 (1.26-4.56)

0.008

Northeast

1.16 (0.66-2.03)

0.6055

Midwest

1.28 (0.76-2.14)

0.3504

South

1.00

.

West

0.96 (0.54-1.68)

0.8724

Yes

2.89 (1.03-8.09)

0.0431

No

1.00

.

On the analysis for reasons cited for not obtaining a mammogram, the most common
reason cited, with 31.01%, was “Never thought about it.” Other reasons cited at least 10% of the
times, in decreasing order, were “Doctor didn’t say I needed it,” “Too expensive, or no
insurance,” “Haven’t had any problems,” and “Put it off.” (Chart and Table 6)
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A significantly lower percentage of women with a first degree family history cited
“Never thought about it” than women without the history (6.71% versus 9.60% P=0.0012), and a
lower percentage with a family history cited “Didn’t need it” than those without the history
(1.72% versus 2.85% p=0.0215). Of those with a family history, 0% cited “Too young” as their
reason for not obtain a mammogram, which was significantly lower than those without a family
history (0% versus 0.60% p<0.0001) (Table 7)
Table 7- Percent make up of all reasons for
no screening mammogram cited
(+) First
Degree
Family
History

(-) First
Degree
Family
History

p value
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Never
thought
about it

6.71

9.6

0.0012

Didn't need
it

1.72

2.85

0.0215

Doctor didn't
say I needed
it

3.32

3.73

0.5355

Haven't had
any
problems
Put it off

2.62
3

2.8
3.41

0.761
0.5222

Too
expensive or
no insurance

3.21

3.79

0.3675

Too
unpleasant

0.76

1.03

0.4087

Too young

0

Don't have a
doctor
Other

0.41
2.3

0.6 <0.0001

0.59
2.23

0.4604
0.8738
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Discussion

In the United States, breast cancer remains the leading malignancy, and despite
widespread public knowledge on screening, the second leading cause of malignancy related
death among women [11]. The incidence of breast cancer since 2006 has been 200 cases per
100,000 women years, and is projected to remain at this level through 2016 [5, 8].

A first degree family history of breast cancer is an important risk factor for future
personal history of breast cancer. Women with a single first degree family member with breast
cancer are 2 to 3 times more likely to suffer breast cancer themselves. The risk increases as the
number of family members with breast cancer increases, and with younger ages at diagnosis
[12-15].

Mammography has been instrumental in reducing mortality from breast cancer.
Estimates from meta-analyses range from 20% to 35% for reduction of breast cancer mortality
[22]. In addition, mammography allows for earlier detection, which then allows for fewer
mastectomies, and lower rates of chemotherapy [47].

While there is the risk of over diagnosis and false positive mammograms [37, 49-51], the
American Cancer Society recommends yearly screening mammograms for all women starting at
age 40 [56], while the United States Preventive Services task Force recommends screening
mammography every two years beginning at age 50 [39].

In women with a first degree family history of breast cancer, those being screened
between ages 39 and 49 had a higher incidence of invasive tumors than the women aged 50 to
60 without a significant family history [63, 64]. Thus, if we hold that mammography is important
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for average risk women aged 50 and older, it is even more important for those women with a
first degree family history, and thus at higher risk, to undergo screening mammography.

The rates of screening mammography have been reported to be declining. From 2000 to
2005, the National Health Interview Survey revealed a decrease of approximately 4% of women
who were screened within the past two years [67]. While some studies indicate the decrease is
limited to lower risk women, there was a decrease in the higher risk cohort that failed to reach
significance [69].

Our study sought to determine if women with a first degree family history of breast
cancer were more likely than women without a first degree family history of breast cancer to
obtain a screening mammogram at least every two years. Further, we sought to determine the
reasons women who did not obtain screening mammography cite for their non-adherence to
recommendations.

Overall, in our study, 78.5% of women over 40 reported obtaining a mammogram in the
previous two years. Of the women 40 years of age and older with a first degree family history,
79.5% reported obtaining a screening mammogram in the previous two years, compared to
78.4% of women without a first degree family history (p=0.452).

Previous studies had also looked at rates of screening mammography in the first degree
family history population compared to the average risk population. For example, an analysis of
the 2005 California Health Interview Survey showed that 83.5% (95% CI 81.0%-85.9%) of women
with a first degree family history of breast cancer obtained a screening mammogram in the
previous 2 years, compared to only 76% (95% CI 74.7%-77.3%) of women at average risk [70].
2005 National Health Interview Survey data had indicated that 79.8% of women with a first
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degree family history had a screening mammogram, while among women without a first degree
family history, only 63.9% had a screening mammogram (p<0.0001) [69]. It would seem from
our data that women with a first degree family history of breast cancer are no longer more likely
to obtain screening mammography than the average risk population.

We looked at sociodemographic factors that were predictive of screening
mammography. For the general population, having insurance, being higher above the poverty
line, having higher education, and reporting a place to go to access preventive care were
associated with higher rates of mammography. Depending on the type of insurance, women
were 1.5-3.7 times as likely as those not covered to obtain a screening mammogram in the past
two years. Being two times above the poverty line was associated with an odds ratio of 1.4
times as likely to have a screening mammogram than those below the poverty line. Increasing
education led to increasing odds ratios compared to non- high school graduates, which reached
significance at the level of a doctorate degree (OR 1.94 95% CI 1.08-3.49). Finally access to
preventive health care was associated with an increased odds of obtaining screening
mammography of 1.66 compared to women without access to preventive care.

Swan et al using 2000 National Health Interview Survey data found that at a rate of
34.6% (95% CI 30.7-38.6%), the women with no usual source of health care had the lowest rates
of screening mammography, while 73.0% (95% CI 71.9-74.1%) of women with a usual source of
care obtained screening mammograms [65]. By comparison with results from the 1987 survey,
those with no usual source of care increased screening mammography rates by only 19.9% (95%
CI 15.0-2.8%) compared with those with a usual source of care who increased their rate by
42.2% (95% CI 40.2-44.2%) [65]. Schueler, from 2005 National Health Interview Survey, similarly
noted that women without a primary care provider were 0.41 times as likely (95% CI 0.32-0.53)
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to have a screening mammogram in the past two years than women with a primary care
provider [71].

We naively believed that women with a first degree family history, with at least twice
the risk of breast cancer, would not allow socioeconomic status to dictate screening behavior.
Perhaps the only predictor would be access to a physician for preventive care, as breast cancer
screening falls under the umbrella of preventive care. Without access to preventive care, they
could not be expected to obtain a preventive care test. However, results of our multivariate of
just the women with a first degree family history yielded much of the same results as the
analysis of the general population. Having insurance was associated with a 2.2 to 3.6 OR in favor
of having a screening mammogram compared to no coverage. Education was not associated
with screening adherence, however, poverty ratio was. Having an income greater than or equal
to two times the poverty line was associated with an odds ratio of 2.39 (95% CI 1.26- 4.56)
compared to those below the poverty line. Access to preventive health care was indeed
associated with improved mammography rates, with an odds ratio of 2.89 (95% CI 1.03-8.09)
compared to no access.

From the California Health Interview Survey in 2005, which had found significantly more
women with a first degree family history undergo screening than those without a family history,
it was noted that lacking insurance and having no physician visit in the previous year were
significantly predictive of lacking a screening mammogram. Just from the first degree family
history population, women without insurance during the previous year were 0.25 times as likely
to obtain a screening mammogram as women who were insured (p<0.01). Not having a
physician predicted a woman was 0.19 times as likely to have a screening mammogram in the
past two years, compared to women who had seen a physician (p<0.01) [71].

34
Another study using the 2000 National Health Interview Survey had looked at similar
variables, and also had found that women without a visit to a doctor in the past year were 0.59
times as likely (95% CI 0.42-0.83) as women with a doctor’s visit to obtain a screening
mammogram in the previous year [72].

Predictors of screening mammography usage, both for the higher risk and the average
risk populations have not changed much in the past ten years. Efforts at improving the societal
infrastructure to help women at risk for lacking care are necessary to remedy this situation. It is
not just screening mammography that is failing to reach the lower socioeconomic status
individuals, however. National Health Interview Survey data from 2000 also indicated that
people without health insurance or access to preventive care were also significantly less likely to
have had a pap smear, or a colonoscopy in the recommended previous screening interval [65].

Our study also looked at reasons women who didn’t have a screening mammogram in
the previous two years cited for their non- adherence. The most commonly reason cited was,
“Never thought about it.” While it was cited significantly less often for the positive first degree
family history cohort than those without a family history (made up 6.71% of responses versus
9.6% of responses, p=0.0012), still 27.89% of women with a first degree family history cited this
as their primary reason. Given that there is an abundance of evidence regarding the increased
risk of breast cancer due to a first degree family history, the finding that over a quarter of higher
risk women “didn’t think about” getting a mammogram should incite public health advocates to
raise awareness in this population.

A meta-analysis of 19 studies on using telephone reminders to increase screening
mammography rates found that the median increase in screening mammography rates resulting
from a telephone reminder was 18.5%, compared to the group that did not receive a reminder
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[73]. These results indicate that reminders may be a tool to increase screening mammography
rates. However, it is unknown what percentage of women in the United States already receives
reminders, so the size of the population the intervention could be used on may be very small.

Another most commonly reason cited is “Doctor didn’t say I needed it.” Whether
because they forgot to order preventive tests, or believed another member of their staff was
handling the order, or there was inaccurate record keeping, or they simply neglected the topic
due to time pressure, it may be true that physicians failed to inform their patients about the
need for a screening mammogram.

Alternatively, the women citing this as a reason may actually reflect poor doctor-patient
communication skills. Doctor patient communication strongly influences a patient’s compliance
with a doctor’s recommendations [74]. A study out of Germany analyzed how interactions
differed between doctors and their high and low socioeconomic patients. They determined that
when communicating with lower socioeconomic status individuals, doctors gave less positive
socio-emotional comments, and interacted in a less conversational, and more directive style
than when communicating with higher socioeconomic status individuals. The style was
characterized by a greater time spent in biomedical speak and less diagnostic and treatment
information given or discussed [75]. So it is entirely possible that the doctors did not effectively
communicate the need for a screening mammogram to their less educated, lower income
patients, leading to lower screening mammography rates.

Finally, that women commonly cited the reason, “Too expensive, or no insurance” is not
surprising given our sociodemographic context. In our study, women below the poverty line
were two thirds as likely as women at two times the poverty line to obtain a screening
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mammogram. Indigent women, regardless of family history are at risk for missing screening
mammograms.

This study is limited by its data source. The National Health Interview Survey is based on
self-report data, and as such, is at risk for overestimating true mammography screening rates.
We already believe the estimated screening rates are too low, so true screening rates would be
even more cause for alarm.

In addition, the method of data collection for why women cite not having a screening
mammogram did not allow for more than one answer. There are likely multiple reasons for a
woman’s difficulty in obtaining screening mammography, and even those with the same
responses likely have nuanced differences based on their own situation.

Still 20.5% of women with a first degree family history of breast cancer did not obtain a
screening mammogram in the recommended interval. Predictors of their screening behavior
correlated with lower socioeconomic status. Public health policy and infrastructure change are
necessary to increase access to care for this group, and promote breast cancer screening
practices.
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